期刊文献+

英芙利昔单抗治疗类风湿关节炎的疗效观察及护理 被引量:4

The therapeutic effect observation and nursing for patients with rheumatic arthritis treated by infliximab
在线阅读 下载PDF
导出
摘要 目的观察英芙利昔单抗治疗类风湿关节炎的疗效与不良反应,探讨生物制剂用药的护理。方法27例类风湿关节患者分别在第0、2、6周及以后每隔8周接受静脉输注3 mg/kg英芙利昔单抗。采用美国风湿病学会疗效评分标准,在用药后第1天、第2周、第6周、第14周进行疗效评定。记录治疗效果及不良反应的预防及处理。结果在用药后第1天、第2周、第6周、第14周ACR20改善程度分别为9例(33%)、14例(44%)、19例(70%)、23例(85%)。不良反应有输液反应3例、呼吸道感染2例、肝功能异常2例、白细胞减少及心脏ST-T改变各1例,经及时干预患者均能积极配合治疗。结论英芙利昔单抗对类风湿关节炎有较好的疗效。严格的用药前评估、正确的给药及密切的观察护理,能提高用药的安全性和耐受性。 Objective To observe the therapeutic effect and side effects of infliximab therapy foe patients with rheumatic arthritis. Method Twenty-seven rheumatic arthritis patients received infliximah by intravenous infusion at the beginning, the 2nd week, the 6th and 14th week, and record and evaluate the therapeutic effect and side effect according to ACR score standard. Result After the first day, 2nd, 6th, and 14th week of treatment, the improvement rate were 33%(9 patients ), 44%(14 patients), 77%(19 patients) and 85%(232 patients) respectively. The side effects included intravenous infusion reaction (3 patients), respiratory tract influence(2 patients), liver function abnormality (2 patients), leucopenia (1 patient) and the isehemic ST--T change of heart(1 patient). Conclusion Infliximab therapy has the satisfactory therapeutic effect for patients with rheumatic arthritis. The careful evaluation before treatment, delivering the drug correctly and the nursing can improve the safety and tolerance.
出处 《护士进修杂志》 北大核心 2009年第21期1932-1934,共3页 Journal of Nurses Training
基金 广东省深圳市医学重点学科建设资助(深卫科发2005C10)
关键词 英芙利昔单抗 类风湿关节炎 疗效 护理 Infliximab Rheumatic arthritis Therapeutic effect Nursing
作者简介 郭粉莲(1971-),女,广东汕头,本科,副主任护师,护士长,从事风湿病的临床护理及护理管理工作 通讯作者:叶志中
  • 相关文献

参考文献9

  • 1Sangha O. Epidem iology of rheumate diseases[J]. Rheumatology. ,2000,39(Supply2) :3-12.
  • 2Maini R N, Breedveid FC, Kalden J R, et al. Sustained improvement over Two Years in Physical Function, Structural Damage, and Signs and Symptoms among Patients with Rheumatoid Arthritis Treated with Infliximab and Methotrexate [J]. Arthritis Rheum, 2004, 50(12): 1051-1065.
  • 3Maini R N, Breedveld F C, Kalden J R, et al. Sustained Improvement over Two Years in Physical Function, Structural Damage, and Signs and Symptoms among Patients with Rheumatoid Arthritis Treated with Infliximab and Methotrexate [J]. Arthritis Rheum, 2004, 50(12): 1051-1065.
  • 4Askling J Fored C M, Brandt L, Baecklund E, et al. Risk and Casecharacteristics of Tuberculosis in Rheumatoid Arthritis Associated with Tumor Necrosis Factor Antagonists in Sweden [J]. Arthritis Rheum, 2005, 52(23):1986-1992.
  • 5Giles J T, Bathon J M. Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases[J]. J Intensive Care Med, 2004, 19(4):320-333.
  • 6K L Hyrich, K D Watson, A J Silman, et al. Predictors of Response to Anti-TNF- Therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register[J]. Rheumatotogy, 2006,45 (16) : 1558-1565.
  • 7Van Der Heijde D, Klareskog L, Rodriguez-Valverde V, etal. Anti-tumor Necrosis Factor Trial In Rheumatoid Arthritis with Concomitant Therapy Study Group. lnfliximab and Methotrexate in the Treatment of Rheumatoid Arthritis[J]. N Engl J Med, 2000, 343(16):1594-1602.
  • 8Rahman M U, Strusberg I, Geusens P, et al. Doubleblinded Infliximab Dose Escalation in Fatients with Rheumatoid Arthritis[J]. Ann Rheum Dis, 2007,66(9):1233-1238.
  • 9Westhovens R, Yoeum D, Hah J, et al. The Safety of Infliximab, Combined with Background Treatments, among Patients with Rheumatoid Arthritis and Various Comorbidities:A Large, Randomized, Placebo-Controlled Trial[J]. Arthritis Rheum, 2006,54(4) : 1075-1086.

同被引文献21

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部